Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL ODT versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL ODT versus MYSOLINE.
LAMICTAL ODT vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine is a triazine derivate that stabilizes presynaptic neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting the release of excitatory neurotransmitters (e.g., glutamate). This suppresses neuronal hyperexcitability and prevents seizure spread.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg daily every 1-2 weeks; maintenance 100-200 mg twice daily (200-400 mg/day). For monotherapy or as add-on in epilepsy and bipolar disorder.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
Terminal elimination half-life: 25-39 hours (single dose), 12-22 hours (with enzyme inducers), 30-70 hours (with valproate); clinically relevant for dosing titration to avoid Stevens-Johnson syndrome
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Primarily hepatic metabolism (glucuronidation by UGT1A4); 70-90% excreted renally as metabolites, 2% unchanged; 2-10% fecal
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant